L-Carnitine in the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-analysis

DiNicolantonio, James J.; Lavie, Carl J.; Fares, Hassan; Menezes, Arthur R.; O’Keefe, James H.

doi:10.1016/j.mayocp.2013.02.007

Cited by 185 publications

(137 citation statements)

References 24 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…In patients with chronic heart failure, the plasma carnitine levels are correlated with %FS, EF, and LVMI [24]. A meta-analysis also revealed that L-carnitine is associated with a 27 % reduction in all-cause mortality and a 40 % reduction in angina symptoms in patients experiencing acute myocardial infarction [25].…”

Section: Effects On Cardiac Parametersmentioning

confidence: 99%

Effects of L-carnitine supplementation on nutritional, immunological, and cardiac parameters in hemodialysis patients: a pilot study

et al. 2015

View full text Add to dashboard Cite

Background: L-carnitine is an essential compound that facilitates the transport of long-chain fatty acid across the inner mitochondrial membrane for β-oxidation. However, the effect of L-carnitine supplementation remains to be fully explored in patients with chronic kidney disease. We aimed in this study to determine the multidirectional effects of L-carnitine supplementation on clinical parameters in more detail. Methods: We orally administered L-carnitine to maintain serum-free carnitine levels within the normal range (30 to 70 μmol/L) for 6 months in 21 hemodialysis (HD) patients (age, 74 ± 11 years; time on HD, 60 ± 84 months).

show abstract

Section: Effects On Cardiac Parametersmentioning

confidence: 99%

Effects of L-carnitine supplementation on nutritional, immunological, and cardiac parameters in hemodialysis patients: a pilot study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…19 The accumulations of mitochondrial long-chain acyl-CoA and long-chain acyl-carnitine have been shown to be reduced by Lcarnitine in ischemic hearts. 20 In a study designed by DiNicolantonio et al, 21 it was demonstrated that L-carnitine compared with placebo was associated with the reduction in all-cause mortality and ventricular arrhythmias (27% and 65%, respectively). Recently, NLR has been reported as a prognostic marker for atrial fibrillation after CABG.…”

Section: Discussionmentioning

confidence: 99%

L-Carnitine Supplementation Reduces Short-Term Neutrophil-Lymphocyte Ratio in Patients Undergoing Coronary Artery Bypass Grafting

Aldemir

Pektaş

Parlar³

et al. 2015

International Surgery

View full text Add to dashboard Cite

This study aims to investigate whether preoperative L-carnitine supplementation affects the neutrophil-to-lymphocyte ratio (NLR) in patients undergoing coronary artery bypass grafting surgery. The neutrophil-to-lymphocyte ratio is an inflammatory marker that has proven usefulness for predicting postoperative complications in coronary artery bypass surgery. A lot of studies concerning the role of L-carnitine in the immune system have been performed, contradictory results have been reported on its effects on absolute numbers of WBC subtypes. This randomized, double-blinded, placebo-controlled study was conducted among patients scheduled for coronary artery bypass grafting surgery between June 2012 and December 2013 in our cardiovascular surgery clinic. A total of 60 consecutive patients were randomized and divided into 2 groups. The first group received 2 g of L-carnitine in 1000 mL of 0.9% saline solution infused over 24 hours for each of the 3 preoperative days (L-carnitine group, n ¼ 30), or only 1000 mL of 0.9% saline solution for the same time period (placebo group, n ¼ 30). The basal values of leukocyte,

show abstract

“…Q10 (25,26) and LC (46) have been used in different heart diseases for decades. Indeed, different mechanisms have been reported for the role of Q10 and LC in hs-CRP, IL-6, lipid profiles, and LVEF in various medical conditions.…”

Section: The Effect Of Q10 Plus Lc Supplementationmentioning

confidence: 99%

“…Myocardium tissue has one of the highest intracellular carnitine concentrations. It should be noted that myocardial carnitine levels are rapidly reduced during MI, and LC supplementation has been revealed to replace depleted myocardial carnitine levels, improve ejection fraction (48), and relieve angina symptoms (46). LC can also upturn mitochondrial transport of fatty acids and reduce availability for triglycerides synthesis that is effective in lipid profiles (24).…”

Section: The Effect Of Q10 Plus Lc Supplementationmentioning

confidence: 99%

Effects of Therapeutic Lifestyle Change Diet and Q10 Plus L-Carnitine Supplementation on Inflammatory Biomarkers of In-Stent Restenosis, Lipid Profile, and Left Ventricular Ejection Fraction in Myocardial Infarction: A Randomized Clinical Trial

Sharifi

Eftekhari

Ostovan

et al. 2017

Iran Red Crescent Med J

View full text Add to dashboard Cite

Background: Following Myocardial Infarction (MI) and percutaneous coronary intervention (PCI), the modification of cardiovascular risk factors and inflammation can improve MI progression and PCI outcomes. Up to now, no certain conclusions have been drawn regarding the effect of therapeutic lifestyle change (TLC) diet and a combination of Q10 plus L-carnitine (LC) supplementation on inflammatory biomarkers of In-Stent Restenosis (ISR), lipid profile, and Left ventricular ejection fraction (LVEF).Objectives: This study aimed to evaluate the effects of TLC diet and Q10 plus LC supplementation on inflammatory biomarkers of ISR, lipid profile, and LVEF following MI and PCI.Methods: This single-blind randomized controlled trial was conducted on 128 subjects. After randomization for treatment allocation, the subjects were divided into the study groups through block randomization. The MI patients were admitted to 2 hospitals, namely Al-Zahra and Kowsar (Shiraz, Iran), between April 2015 and May 2016. The patients were divided into 4 groups receiving TLC diet (A), oral Q10 150 mg/d and LC 1200 mg/d (B), a combination of LC plus Q10 and TLC diet (C), and the routine care (D). This study evaluated Interleukin-6 (IL-6) and high sensitive C-reactive protein (hs-CRP) as inflammatory biomarkers of ISR, lipid profile, and LVEF in 128 patients with MI undergoing PCI before and 3 months after the intervention. Results:The results showed a significant decrease in hs-CRP in groups B (11.8 ± 4.3 to 2.0 ± 1 mg/L) and C (11.7±3.9 to 1.3±1.1 mg/L) (P < 0.0001 and P < 0.0001, respectively), but not in group A. Also, a significant reduction was found in IL-6 in groups A (38.0 ± 15 to 9.4 ± 2 pg/mL), B (34.6 ± 12 to 5.1 ± 2.4 pg/mL), and C (33.7 ± 12 to 4.8 ± 2.1 pg/mL) (P < 0.0001, P < 0.0001, and P < 0.0001, respectively). Additionally, LDL and total cholesterol, but not TG, levels significantly decreased in groups A (150 ± 17 to 80 ± 13 mg/dL), B (148 ± 15 to 77.2 ± 14 mg/dL), and C (142 ± 11 to 64.8 ± 10 mg/dL) (P < 0.0001, P < 0.001, and P < 0.0001, respectively). Nevertheless, only group C showed a significant improvement in LVEF (45.1 ± 8 to 53.6 ± 8) (P < 0.027).Conclusions: An adjuvant therapy with TLC diet and supplementation with Q10 and LC seems to be required for secondary prevention following MI and PCI. TLC diet and Q10 plus LC appeared to be effective in inflammatory biomarkers of ISR as well as LDL reduction.

show abstract

L-Carnitine in the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-analysis

Cited by 185 publications

References 24 publications

Effects of L-carnitine supplementation on nutritional, immunological, and cardiac parameters in hemodialysis patients: a pilot study

Effects of L-carnitine supplementation on nutritional, immunological, and cardiac parameters in hemodialysis patients: a pilot study

L-Carnitine Supplementation Reduces Short-Term Neutrophil-Lymphocyte Ratio in Patients Undergoing Coronary Artery Bypass Grafting

Effects of Therapeutic Lifestyle Change Diet and Q10 Plus L-Carnitine Supplementation on Inflammatory Biomarkers of In-Stent Restenosis, Lipid Profile, and Left Ventricular Ejection Fraction in Myocardial Infarction: A Randomized Clinical Trial

Contact Info

Product

Resources

About